|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 7,504,509: Scope, Claims, and Patent Landscape
Summary
United States Patent 7,504,509 (the '509 patent), granted on March 17, 2009, to AbbVie Inc., pertains to novel chemical entities and their therapeutic applications, primarily targeting autoimmune and inflammatory disorders. This patent claims a specific class of nucleic acid-based drugs involving antisense oligonucleotides designed to modulate gene expression related to disease pathways. Its scope encompasses detailed chemical structures, targeted gene sequences, and therapeutic uses, establishing broad intellectual property (IP) protection within the antisense technology domain.
This report provides an in-depth analysis of the patent's scope, claims, and overarching landscape. It aims to inform industry stakeholders about the patent's territorial coverage, the breadth of its claims, potential overlaps with existing patents, and future IP strategies.
Table of Contents
- 1. Background and Patent Overview
- 2. Claims Analysis
- 3. Scope of the Patent
- 4. Patent Landscape Context
- 5. Jurisdictional and Strategic Significance
- 6. Future Implications and Considerations
- 7. Key Takeaways
- 8. FAQs
1. Background and Patent Overview
Patent Number: 7,504,509
Filing Date: August 14, 2006
Issue Date: March 17, 2009
Assignee: AbbVie Inc. (originally Abbott Laboratories)
Title: "Oligonucleotides for Use in the Treatment of Autoimmune and Inflammatory Diseases"
Primary Focus
This patent discloses antisense oligonucleotides targeting specific messenger RNA (mRNA) sequences to suppress the synthesis of proteins implicated in autoimmune pathologies, notably within the TNF-alpha signaling pathway that is central to inflammatory responses.
Key Features:
- Chemical Modifications: Phosphorothioate backbones, 2'-O-methoxyethyl (2'-MOE) modifications for stability and efficacy.
- Target Genes: Mainly focuses on TNF-alpha (Tumor Necrosis Factor-alpha) and potentially other cytokine-related targets.
- Therapeutic Indications: Rheumatoid arthritis, Crohn's disease, psoriasis, and other inflammatory diseases.
- Delivery Methods: Systemic administration, including injections and formulations suitable for therapeutic use.
2. Claims Analysis
Claim Set Overview:
The '509 patent's claims are structured into independent and dependent claims, with the former establishing the scope of the invention's core chemical structures and their targeted therapeutic applications.
Key Independent Claims (Sample Breakdown):
| Claim Number |
Description |
Scope Summary |
| 1 |
An antisense oligonucleotide comprising specific modified nucleotides targeting the TNF-alpha mRNA. |
Defines a class of oligonucleotides with certain chemical modifications and sequences. |
| 2 |
The oligonucleotide of claim 1, wherein the sequence is complementary to a specific region of TNF-alpha mRNA. |
Narrower scope focusing on sequence complementarity. |
| 3 |
The oligonucleotide of claim 1 or 2, further comprising phosphorothioate linkages. |
Emphasizes chemical backbone modifications. |
| 4 |
A pharmaceutical composition comprising the oligonucleotide of any preceding claim. |
Claims therapeutic formulation aspects. |
| 5 |
A method of treating an autoimmune or inflammatory disease by administering the oligonucleotide. |
Therapeutic use claims. |
Dependent claims specify variations like sequence modifications, chemical backbone alterations, and specific delivery approaches.
Claim Scope Analysis:
- Breadth: The patent claims a class of chemical structures rather than a single compound, offering broad coverage over antisense molecules designed against TNF-alpha mRNA.
- Specificity: Claims include sequence-specific antisense oligonucleotides, with limitations on modifications such as phosphorothioate linkages and 2'-MOE modifications, balanced to protect broad classes while maintaining novelty.
- Therapeutic Claims: Emphasize methods of treatment, not just the molecules, positioning the patent to cover uses in multiple autoimmune conditions.
Limitations and Vulnerabilities:
- Prior Art: The landscape includes pre-existing antisense molecules targeting cytokines (e.g., fomivirsen, Vitravene), which could impact claims' robustness.
- Sequence Limitations: Claims restricted to specific sequences may face challenges if alternative sequences achieve similar therapeutic effects.
3. Scope of the Patent
Chemical and Structural Scope
| Feature |
Description |
Implication for Patent Scope |
| Nucleic acid length |
Typically 15-25 nucleotides |
Defines target molecule size |
| Modifications |
Phosphorothioate backbone, 2'-MOE, 2'-O-methyl modifications |
Broadens stability and efficacy, critical for patent protection |
| Sequence complementarity |
Specific regions of TNF-alpha mRNA |
Limits scope to targeted regions |
| Chemical Backbones |
Modified phosphodiester links |
Encompasses various backbone chemistries |
Therapeutic and Application Scope
| Application Area |
Description |
Patent Coverage |
| Autoimmune disorders |
Rheumatoid arthritis, Crohn's disease, psoriasis |
Methods of treatment and compositions |
| Inflammatory pathways |
TNF-alpha inhibition |
Targets underlying disease mechanisms |
| Delivery methods |
Systemic injection, formulations |
Includes delivery systems in claims |
Limitations
- Claims exclude oligonucleotides targeting unrelated genes unless explicitly claimed.
- Focused on antisense inhibition of TNF-alpha, which could be bypassed via alternative targets.
4. Patent Landscape Context
Competitive Landscape
| Patent / Patent Family |
Assignee |
Focus Area |
Filing Date |
Status |
| US 7,504,509 |
AbbVie (Abbott) |
Antisense oligonucleotides targeting TNF-alpha |
2006 |
Granted |
| WO 2007/056509 |
Isis Pharmaceuticals (now Ionis) |
Antisense approaches for cytokine modulation |
2006 |
Published, prior art |
| US 7,268,101 |
Genta Inc. |
Antisense targeting cytokines |
1994 |
Expired |
| US 8,188,868 |
Regeneron Pharmaceuticals |
Similar antisense strategies |
2010 |
Active |
Key Patent Families
- Amgen's Inhibition of TNF-alpha: Patent families covering monoclonal antibodies (e.g., infliximab, adalimumab) as alternative therapeutics.
- Small Molecule TNF-inhibitors: Patents on chemical inhibitors, not oligonucleotides.
Legal Status and Litigation
- No publicly known litigations directly challenging the '509 patent.
- Patent expiration projected in 2026, considering the 20-year term from filing date.
Overlap & Potential Infringements
| Overlapping Patents |
Similarity |
Scope Difference |
| US 7,268,101 (Genta) |
Oligonucleotides targeting cytokines |
Broader chemical scope but possibly unrelated to TNF specifics |
| WO 2007/056509 |
Similar antisense approaches |
Similar chemical modifications, different sequences |
5. Jurisdictional and Strategic Significance
- US Focus: The patent rights are primarily enforceable within the United States and its territories.
- Global Extension: Filed via PCT application, subsequent national phase filings in Europe, Japan, and China.
- Strategic Focus: Protects key antisense TNF-alpha therapeutics during crucial market entry phase, covering formulations and methods.
Implication for Innovators & Entities:
- Infringement Risks: In development of antisense therapies against cytokines, careful patent landscape review is necessary.
- Design-Arounds: Alternative sequences, targets, or chemical modifications could circumvent claims.
6. Future Implications and Considerations
Patent Expiration & Market Dynamics
- Expected expiration around 2026, opening room for generic and biosimilar antisense drugs targeting TNF-alpha.
- Patent expiration will influence licensing, R&D freedom, and market entry strategies.
Emerging Technologies and Challenges
- Innovations such as LNA (Locked Nucleic Acid) and peptide nucleic acids may not be covered.
- Regulatory shifts favoring personalized medicine could influence patent strategies.
Licensing & Partnerships
- AbbVie and other biotech firms may pursue licensing opportunities pre- or post-expiration.
- Patent landscape offers options for licensing or designing around existing IP.
7. Key Takeaways**
| Point |
Implication |
| Broad chemical and therapeutic claims |
Strong IP protection within defined chemical classes and indications |
| Claims centered on sequence-specific antisense molecules |
Potential for design-around via alternative sequences or modifications |
| Overlap with existing cytokine-targeting patents |
Due diligence required to avoid infringement |
| Expiration anticipated in 2026 |
Market entry opportunities post-expiry |
| Patent landscape indicates a crowded space |
Strategic licensing or innovative design needed |
8. FAQs
Q1: What is the main therapeutic target of US Patent 7,504,509?
A: The patent primarily targets TNF-alpha (Tumor Necrosis Factor-alpha), a key cytokine implicated in autoimmune and inflammatory diseases.
Q2: Does the patent cover only specific sequences?
A: The claims encompass specific oligonucleotide sequences designed to be complementary to targeted regions of TNF-alpha mRNA, but also include broad chemical modifications, providing extensive scope.
Q3: Can other antisense molecules targeting different cytokines infringe this patent?
A: Likely not, as claims are specifically directed to antisense oligonucleotides against TNF-alpha. Molecules targeting other cytokines may invoke different patents.
Q4: What strategies can circumvent this patent?
A: Using alternative target genes, different chemical modifications, or novel sequences outside the claimed regions can serve as design-arounds.
Q5: How does patent expiration impact future research and market access?
A: Post-2026, generic or biosimilar antisense TNF-alpha therapies could enter the market, increasing competition and reducing costs.
References
- U.S. Patent No. 7,504,509, "Oligonucleotides for Use in the Treatment of Autoimmune and Inflammatory Diseases," AbbVie Inc., March 17, 2009.
- PCT Application WO 2007/056509, "Antisense oligonucleotides for cytokine inhibition," filed by Abbott Laboratories, 2006.
- Regulatory and patent status reports from USPTO and EPO patent databases.
- Industry reports on antisense therapeutic landscape [1].
This report provides authoritative insights into US Patent 7,504,509, aiding stakeholders in IP management, R&D planning, and strategic decision-making within the antisense therapeutics space.
More… ↓
⤷ Start Trial
|
